TumorCardiovascular DiseasesPulmonary FibrosisRheumatic Immune Diseases Involving Large Blood VesselsHypertrophic Cardiomyopathy (HCM)Other Hypoxic and Fibroblast Activated Diseases
Investigational drug(s) / intervention(s)
Injection of 68Ga-NI-FAPI
Injection of 68Ga-NI-FAPI: Subjects were injected with 68Ga-NI-FAPI at 0.4-0.5mci/kg body weight
Study summary
The purpose of this study is to conduct clinical research on \[68Ga\] Ga-NI-FAPI-04 PET/CT imaging and further investigate its diagnostic value in fibroblast activation related diseases.
Eligibility
Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* 1: 18-85 years old
2: Tumor patients can undergo surgery or biopsy to obtain pathological diagnosis
3: Ability to understand and sign informed consent forms
4: Expected survival period exceeding 6 months and able to receive follow-up
5: Healthy volunteers without chronic medical history of hypertension, diabetes, coronary heart disease, kidney disease, tumor, etc
Exclusion Criteria:
* 1: Pregnant or lactating women
2: Patients allergic to research drug ingredients
3: Patients with severe liver and kidney dysfunction (blood creatinine levels exceeding 159 μ mol/L)
4: Patients who participate in other clinical trials and interfere with the results of this study
5: Patients with severe illness who cannot cooperate with the examination
Primary outcome measure(s)
Analysis of PET/CT Images of [68Ga] Ga-NI-FAPI-04 — Within 30-120 minutes after intravenous injection of imaging agent Semi quantitative analysis (measuring lesion standard uptake value (SUV), then calculating lesion SUV to liver/blood pool SUV ratio)
Trial sites (1)
Facility
City
Region
Status
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing
Beijing Municipality
Recruiting
More Peking Union Medical College Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.